The global spatial OMICS market size is calculated at USD 307.40 million in 2024, grew to USD 339.98 million in 2025, and is predicted to hit around USD 841.89 million by 2034, poised to grow at a CAGR of 10.6% between 2024 and 2034. The North America spatial OMICS market size accounted for USD 125.07 million in 2024 and is anticipated to grow at the fastest CAGR of 10.7% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Spatial OMICS Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Spatial OMICS Market Revenue and Volume Forecast, by Application, 2024-2034
8.1.1. Diagnostics
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. Translation Research
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
8.1.3. Drug Discovery and Development
8.1.3.1. Market Revenue and Volume Forecast (2021-2034)
8.1.4. Single Cell Analysis
8.1.4.1. Market Revenue and Volume Forecast (2021-2034)
8.1.5. Cell Biology
8.1.5.1. Market Revenue and Volume Forecast (2021-2034)
8.1.6. Other
8.1.6.1. Market Revenue and Volume Forecast (2021-2034)
9.1. Spatial OMICS Market Revenue and Volume Forecast, by Solution Type, 2024-2034
9.1.1. Instruments
9.1.1.1. Market Revenue and Volume Forecast (2021-2034)
9.1.2. Consumables
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
9.1.3. Software
9.1.3.1. Market Revenue and Volume Forecast (2021-2034)
10.1. Spatial OMICS Market Revenue and Volume Forecast, by Sample, 2024-2034
10.1.1. DNA
10.1.1.1. Market Revenue and Volume Forecast (2021-2034)
10.1.2. RNA
10.1.2.1. Market Revenue and Volume Forecast (2021-2034)
10.1.3. Protein
10.1.3.1. Market Revenue and Volume Forecast (2021-2034)
11.1. Spatial OMICS Market Revenue and Volume Forecast, by End Users, 2024-2034
11.1.1. Academic and Research Institutions
11.1.1.1. Market Revenue and Volume Forecast (2021-2034)
11.1.2. Biopharmaceutical & Biotechnological Companies
11.1.2.1. Market Revenue and Volume Forecast (2021-2034)
11.1.3. Contract Research Organization
11.1.3.1. Market Revenue and Volume Forecast (2021-2034)
11.1.4. Other
11.1.4.1. Market Revenue and Volume Forecast (2021-2034)
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by Application (2021-2034)
12.1.2. Market Revenue and Volume Forecast, by Solution Type (2021-2034)
12.1.3. Market Revenue and Volume Forecast, by Sample (2021-2034)
12.1.4. Market Revenue and Volume Forecast, by End Users (2021-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by Application (2021-2034)
12.1.5.2. Market Revenue and Volume Forecast, by Solution Type (2021-2034)
12.1.5.3. Market Revenue and Volume Forecast, by Sample (2021-2034)
12.1.5.4. Market Revenue and Volume Forecast, by End Users (2021-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by Application (2021-2034)
12.1.6.2. Market Revenue and Volume Forecast, by Solution Type (2021-2034)
12.1.6.3. Market Revenue and Volume Forecast, by Sample (2021-2034)
12.1.6.4. Market Revenue and Volume Forecast, by End Users (2021-2034)
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by Application (2021-2034)
12.2.2. Market Revenue and Volume Forecast, by Solution Type (2021-2034)
12.2.3. Market Revenue and Volume Forecast, by Sample (2021-2034)
12.2.4. Market Revenue and Volume Forecast, by End Users (2021-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by Application (2021-2034)
12.2.5.2. Market Revenue and Volume Forecast, by Solution Type (2021-2034)
12.2.5.3. Market Revenue and Volume Forecast, by Sample (2021-2034)
12.2.5.4. Market Revenue and Volume Forecast, by End Users (2021-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by Application (2021-2034)
12.2.6.2. Market Revenue and Volume Forecast, by Solution Type (2021-2034)
12.2.6.3. Market Revenue and Volume Forecast, by Sample (2021-2034)
12.2.6.4. Market Revenue and Volume Forecast, by End Users (2021-2034)
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by Application (2021-2034)
12.2.7.2. Market Revenue and Volume Forecast, by Solution Type (2021-2034)
12.2.7.3. Market Revenue and Volume Forecast, by Sample (2021-2034)
12.2.7.4. Market Revenue and Volume Forecast, by End Users (2021-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by Application (2021-2034)
12.2.8.2. Market Revenue and Volume Forecast, by Solution Type (2021-2034)
12.2.8.3. Market Revenue and Volume Forecast, by Sample (2021-2034)
12.2.8.4. Market Revenue and Volume Forecast, by End Users (2021-2034)
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by Application (2021-2034)
12.3.2. Market Revenue and Volume Forecast, by Solution Type (2021-2034)
12.3.3. Market Revenue and Volume Forecast, by Sample (2021-2034)
12.3.4. Market Revenue and Volume Forecast, by End Users (2021-2034)
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by Application (2021-2034)
12.3.5.2. Market Revenue and Volume Forecast, by Solution Type (2021-2034)
12.3.5.3. Market Revenue and Volume Forecast, by Sample (2021-2034)
12.3.5.4. Market Revenue and Volume Forecast, by End Users (2021-2034)
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by Application (2021-2034)
12.3.6.2. Market Revenue and Volume Forecast, by Solution Type (2021-2034)
12.3.6.3. Market Revenue and Volume Forecast, by Sample (2021-2034)
12.3.6.4. Market Revenue and Volume Forecast, by End Users (2021-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by Application (2021-2034)
12.3.7.2. Market Revenue and Volume Forecast, by Solution Type (2021-2034)
12.3.7.3. Market Revenue and Volume Forecast, by Sample (2021-2034)
12.3.7.4. Market Revenue and Volume Forecast, by End Users (2021-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by Application (2021-2034)
12.3.8.2. Market Revenue and Volume Forecast, by Solution Type (2021-2034)
12.3.8.3. Market Revenue and Volume Forecast, by Sample (2021-2034)
12.3.8.4. Market Revenue and Volume Forecast, by End Users (2021-2034)
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by Application (2021-2034)
12.4.2. Market Revenue and Volume Forecast, by Solution Type (2021-2034)
12.4.3. Market Revenue and Volume Forecast, by Sample (2021-2034)
12.4.4. Market Revenue and Volume Forecast, by End Users (2021-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by Application (2021-2034)
12.4.5.2. Market Revenue and Volume Forecast, by Solution Type (2021-2034)
12.4.5.3. Market Revenue and Volume Forecast, by Sample (2021-2034)
12.4.5.4. Market Revenue and Volume Forecast, by End Users (2021-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by Application (2021-2034)
12.4.6.2. Market Revenue and Volume Forecast, by Solution Type (2021-2034)
12.4.6.3. Market Revenue and Volume Forecast, by Sample (2021-2034)
12.4.6.4. Market Revenue and Volume Forecast, by End Users (2021-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by Application (2021-2034)
12.4.7.2. Market Revenue and Volume Forecast, by Solution Type (2021-2034)
12.4.7.3. Market Revenue and Volume Forecast, by Sample (2021-2034)
12.4.7.4. Market Revenue and Volume Forecast, by End Users (2021-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by Application (2021-2034)
12.4.8.2. Market Revenue and Volume Forecast, by Solution Type (2021-2034)
12.4.8.3. Market Revenue and Volume Forecast, by Sample (2021-2034)
12.4.8.4. Market Revenue and Volume Forecast, by End Users (2021-2034)
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by Application (2021-2034)
12.5.2. Market Revenue and Volume Forecast, by Solution Type (2021-2034)
12.5.3. Market Revenue and Volume Forecast, by Sample (2021-2034)
12.5.4. Market Revenue and Volume Forecast, by End Users (2021-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by Application (2021-2034)
12.5.5.2. Market Revenue and Volume Forecast, by Solution Type (2021-2034)
12.5.5.3. Market Revenue and Volume Forecast, by Sample (2021-2034)
12.5.5.4. Market Revenue and Volume Forecast, by End Users (2021-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by Application (2021-2034)
12.5.6.2. Market Revenue and Volume Forecast, by Solution Type (2021-2034)
12.5.6.3. Market Revenue and Volume Forecast, by Sample (2021-2034)
12.5.6.4. Market Revenue and Volume Forecast, by End Users (2021-2034)
13.1. NanoString Technologies, Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Illumina, Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. 10x Genomics, Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Akoya Biosciences, Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Visiopharm A/S
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. GE Healthcare
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Fluidigm Corporation
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Advanced Cell Diagnostics, Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. PerkinElmer, Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. ZEISS Group
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample